Fetal Hemoglobin Inducer Compounds With Lower Toxicity Risk
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for hemoglobinopathies, such as sickle cell disease and beta-thalassemia, are limited by variable clinical responses and risks like myelotoxicity and carcinogenesis, necessitating the development of more effective therapies.
Innovation Solution
Development of compounds of formulas (I), (II), and (III), along with their pharmaceutically acceptable salts, tautomers, and stereoisomers, which are administered to induce fetal hemoglobin expression in adult hematopoietic cells, thereby treating or preventing hemoglobinopathies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If hydroxyurea is used to induce fetal hemoglobin expression, then fetal hemoglobin production is improved, but myelotoxicity and carcinogenesis risk increase
Solution Approach 1:
The patent modifies the chemical structure of hydroxyurea derivatives by changing molecular parameters (adding specific functional groups and substituents) to alter the drug's biological activity. This allows maintaining fetal hemoglobin induction while reducing toxic effects through precise chemical parameter modification.
Solution Approach 2:
The patent introduces intermediary compounds (hydroxyurea derivatives with specific side chains) that act as mediators between the desired therapeutic effect and the avoidance of toxicity. These intermediary structures enable selective fetal hemoglobin induction while minimizing damage to normal bone marrow cells.
2Reliability
If blood transfusions are used to treat beta-thalassemia, then hemoglobin deficiency is improved, but iron overload complications increase
Solution Approach 1:
The patent converts the harmful effect of iron overload into a benefit by using compounds that induce fetal hemoglobin expression, which naturally reduces the need for repeated blood transfusions. This approach eliminates the source of iron overload (transfusion) while treating the underlying hemoglobin deficiency.
Solution Approach 2:
The patent enables the body's own hematopoietic system to produce functional hemoglobin through fetal hemoglobin induction, making the system self-sufficient and eliminating the need for external blood transfusions that cause iron overload.
3Ease of manufacture
If conventional treatments are used for hemoglobinopathies, then treatment availability is improved, but clinical response variability increases
Solution Approach 1:
The patent applies local quality by designing compounds with specific molecular features tailored to interact with particular transcription factors (like BCL11A and JSF1) in a localized manner. This specificity ensures consistent clinical response by targeting the precise molecular mechanism responsible for fetal hemoglobin regulation.
Data Source
AI summary
Disclosed herein are compounds and methods for the prevention and/or treatment of hemoglobinopathies. Also provided herein are such compounds for use in such methods. Also disclosed herein are pharmaceutical compositions comprising such compounds for use in such methods of preventing or treating hemoglobinopathies.